ALCL-VBL (anaplastic large cell lymphoma)
Recruiting
Who can enter
Children with ALK+ anaplastic large-cell lymphoma (ALCL) at standard risk at initial diagnosis
Children up to 18 years old
Goal
Goal
The aim of this study is to improve the treatment of children with lymphoma. We will investigate whether treatment with only vinblastine gives the same result as treatment with chemotherapy courses with different drugs. We will also look at the side effects of treatment with vinblastine alone.
Background
Background
Vinblastine is approved for treatment of different types of tumors and lymphomas in adults and children. In a previous study, vinblastine was also tested in children with ALCL where the disease had returned after previous treatment (recurrence). After treatment with vinblastine, about 80% of these patients had no recurrence. In this study, we want to see if vinblastine also works well in children who have not had any previous treatment.
Normally, we treat children with standard-risk ALCL at initial diagnosis with chemotherapy courses of various drugs. This treatment gives good results, but also causes many side effects. In this study, we want to see if treatment with vinblastine alone has as good a result as chemotherapy courses with several drugs. We will also look at the side effects.
All children participating in the study will be treated with the medicine vinblastine. The treatment lasts two years.
In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Patients Office.
Last reviewed
Last reviewed
March 16, 2026
Study details
- Study details
Official title
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of VinblastineCancer type
Anaplastic large-cell lymphoma (ALCL)Phase
3Maximum number of patients
106 patients, of whom 10 are expected to participate in the NetherlandsStart date
November 4, 2022Status
OpenLocal principal investigator
Dr. M.A. VeeningSponsor
German Pediatric Oncology Group (GPOH gGmbH), GermanyApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
Clinicaltrialsregister.eu: 2017-002935-40
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.